Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa.
Using a broth microdilution method, we compared the in vitro activity of lomefloxacin to other broad spectrum antimicrobials against clinical strains of Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and P. aeruginosa. Against the Enterobacteriaceae and A. hydrophila, lomefloxacin showed excellent activity with MIC50 values ranging from 0.12-0.5 micrograms/ml and MIC90 values ranging from 0.12-1.0 micrograms/ml. By comparison, lomefloxacin had superior activity to nalidixic acid and difloxacin, comparable activity to norfloxacin and fleroxacin, and slightly less activity than ciprofloxacin. Lomefloxacin was also more active than imipenem, ceftazidime, aztreonam, ticarcillin/clavulanic acid (T-CA), and gentamicin. Lomefloxacin was less active (MIC90, 4 micrograms/ml) against Acinetobacter strains than Enterobacteriaceae strains. Against these same Acinetobacter strains, lomefloxacin was 8- to 64-fold more active than ceftazidime, aztreonam, T-CA, and gentamicin but slightly less active than imipenem. Lomefloxacin was 2- to 8-fold more active than fleroxacin, difloxacin, and nalidixic acid against strains of P. aeruginosa. However, lomefloxacin was less active than ciprofloxacin and norfloxacin. Lomefloxacin had comparable activity to imipenem but was 2- to 16-fold more active than ceftazidime, aztreonam, T-CA, and gentamicin. Thus, lomefloxacin demonstrated comparable activity to other fluorinated quinolones in that it possesses high active against clinical strains of Enterobacteriaceae and had good-to-moderate activity against most strains of Acinetobacter and P. aeruginosa.